ArticleBMJ open2021

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.

Jeroen H A Creemers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.